Cerity Partners
ADMA icon

Cerity Partners’s ADMA Biologics ADMA Stock Holding History

Cerity Partners’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$268K Sell
32,031
-6,116
-16% -$55.8K ﹤0.01% 2871
2026
Q1 		$344K Sell
38,147
-4,167
-10% -$65.8K ﹤0.01% 2512
2025
Q4 		$772K Buy
42,314
+1,266
+3% +$21.3K ﹤0.01% 1836
2025
Q3 		$602K Sell
41,048
-7,524
-15% -$129K ﹤0.01% 1863
2025
Q2 		$884K Buy
48,572
+869
+2% +$17.7K ﹤0.01% 1576
2025
Q1 		$946K Buy
47,703
+4,575
+11% +$79.1K ﹤0.01% 1448
2024
Q4 		$762K Sell
43,128
-7,750
-15% -$146K ﹤0.01% 1544
2024
Q3 		$1.02M Buy
50,878
+30,637
+151% +$476K ﹤0.01% 1388
2024
Q2 		$226K Buy
20,241
+2,783
+16% +$23.3K ﹤0.01% 1968
2024
Q1 		$115K Buy
17,458
+7,458
+75% +$40.8K ﹤0.01% 2191
2023
Q4 		$45.2K Sell
10,000
-300
-3% -$1.11K ﹤0.01% 1817
2023
Q3 		$36.9K Buy
10,300
+300
+3% +$1.16K ﹤0.01% 1367
2023
Q2 		$36.9K Buy
+10,000
New +$37.1K ﹤0.01% 1587

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Cerity Partners's ADMA Position: Q2 2026 in Review

Cerity Partners reduced its ADMA Biologics (ADMA) stake by 16% in Q2 2026, selling an estimated $55.8K and leaving 32,031 shares worth $268K. The position accounts for ﹤0.01% of the portfolio, ranked #2871.

Cerity Partners first reported a position in ADMA in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.02M in Q3 2024. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Cerity Partners held 32,031 shares of ADMA Biologics worth $268K as of Q2 2026.
  • Cerity Partners sold 6,116 ADMA Biologics shares in Q2 2026, an estimated $55.8K.
  • ADMA Biologics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2871 holding.
  • Cerity Partners first reported a position in ADMA Biologics in Q2 2023 and has held it in 13 quarters since.
  • Cerity Partners's ADMA Biologics position peaked at $1.02M in Q3 2024.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.